Canon Medical Systems Corporation will start clinical application evaluation of diagnostic support for new coronavirus pneumonia using CT image analysis technology for diffuse lung disease developed in collaboration with Professor Ryoji Ohno of Fujita Medical University. Announced.
The findings on CT images of the new coronavirus pneumonia are often reported to be characteristic of interstitial pneumonia.In particular, information such as the existence, shape, and location of high-concentration shadows such as ground glass shadows and infiltration shadows is useful for diagnosing the new coronavirus.However, CT interpretation of lung disease has a problem of low concordance rate among interpreters, and there is a possibility that medical provision may differ.
The jointly developed CT texture analysis technology uses CT images to identify and quantify the morphological characteristics of the lungs by machine learning from the shadow and shape information of the lungs resulting from various lung diseases.It has already been reported as basic research results that there is a correlation between the severity of interstitial pneumonia and the quantitative results of the analysis, and that the radiologist and the analysis have a sufficient degree of agreement.
From the end of July 2020, we will analyze cases of suspected new coronavirus pneumonia and proceed with clinical application evaluation.By combining Canon Medical Systems' X-ray CT equipment with low exposure and high image quality and jointly developed analysis technology, it is said that it will promote support for quick, safe and accurate diagnosis.
In addition to this report, Fujita Health University reported on July 7 a tentative analysis of the final results of clinical trials conducted nationwide regarding the anti-influenza virus agent avigan (generic name favipiravir).The purpose of the study was to examine the viral load reduction effect of Avigan in asymptomatic and mildly ill patients infected with the new coronavirus.The analysis showed a tendency to eliminate the virus and reduce fever, but it was reported that the difference was not statistically significant.
reference:[Canon Medical Systems Corporation] Started clinical application evaluation of new coronavirus pneumonia diagnosis support
[Fujita Medical University] About the final report of favipiravir (Abigan) specific clinical research
